2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Stigma in Parkinson's disease: Placing it outside the body

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Stigma in Parkinson's disease Parkinson's Disease (PD) has traditionally been characterized by its motor symptoms (e.g., bradykinesia, rigidity, and tremor), 1 however the disease burden also comprises other non-motor symptoms 2 and psycho-social problems that can negatively impact patients Health-Related Quality of Life. 3 A significant one is a stigma which both PD and caregivers experience due to their condition. Stigma could be defined as an attribute implying a discredit of the individual who is considered “bad, weak or dangerous”, reducing it to a representation from a whole and usual person to a tainted one. 4 As a matter, more than 50% of patients with PD conceal their diagnosis, 5 trying to mask some of their clinical symptoms[6] or even avoid appearing in public. 7 This stigma emanates from the interplay between patient and environment, where stigmas place the burden on the stigmatized subject. 8 , 9 Like any other neuropsychiatric disease, PD is a categorization tool used by physicians and researchers for a better understanding of this phenomenon and the development of effective therapies and care. However, this tool is embedded in social, cultural, and political dimensions, which directly affect the construction of stigma against these populations. Efforts are made by researchers and clinicians in order to minimize the effect stigma has on patient wellbeing and quality of life, often analyzing how some disease characteristics like severity of motor symptoms or emotional disorders affect this situation. Despite the direct relation patient functional and bodily states may have with stigma, the authors should consider this socio-cultural component intrinsic to this phenomenon in order to accurately approach a solution. Clinical symptoms observed in PD patients can lead to communicative and social disruptions, 10 especially those symptoms related to emotion expression and recognition like facial masking, constituting what has been named as ‘social symptoms of PD’, 11 which largely contribute to stigma experience. In this line, clinical research has also explored how stigma could be predicted from disease characteristics like depression, 12 , 13 low scores in Activities of Daily Living (ADL), 12 , 14 or severe motor symptoms. 13 , 15 These associations between clinical symptoms and stigma are usually followed by the logical conclusion that ameliorating those symptoms is the path to take to effectively reduce stigma in PD patients, further suggesting the collection of more biomedical variables with the potential to emerge as predictors of stigma. Besides the evident impact motor symptoms improvement could have on experienced stigma in PD patients, studying stigma solely through the analysis of symptoms and functional capacities of patients places the burden of stigma on the bodies of patients, largely neglecting the socio-cultural dimension intrinsic to stigma phenomenon. 8 Authors are often aware of this conflict, as they state the importance of this socio-cultural dimension, while at the same time, the variables explored relate almost exclusively to patients’ bodies, and the socio-cultural aspect remains unexplored. Despite the focus on clinical symptoms associated with stigma in PD, these studies also reported differences in the few social variables they collected like gender[13] or age, 13 , 14 reinforcing the standpoint of stigma as socio-cultural informed. Results also showed how emotional disorders were robust predictors of stigma, 12 , 13 which are largely affected by social discrimination. 16 . This gap between the socio-cultural dimension of stigma and the bodily states of patients reflects the relation between epistemology and ontology within biomedical research and practice, showing how the production of knowledge could be influenced by socio-cultural contexts. Therefore, the authors need approaches that tackle this complexity, further exploring this aspect of stigma. The review of Maffoni et al. 17 try to describe a new understanding of stigma from an intercultural and social viewpoint, moving to a patient-centered approach that contextualizes clinical symptoms within a broader dimension of socio-cultural interactions. This kind of understanding of stigma in PD is present in other studies, 11 where authors also stress the importance of properly identifying stigma when it is invisible to physicians. 6 Henry et al. 18 reported differences in stigma between Mexico and USA patients and caregivers, showing potential cultural differences of stigma. The authors share with these authors the notion of stigma as a subjective symptom, which, besides its relationship with clinical symptoms, emerges mainly from the interaction between individuals and society as a whole. Clinicians and researchers are also social actors embedded in socio-cultural environments regarding the biomedical care they deliver. In addition to the treatment of motor and non-motor symptoms, which largely impact patients' wellbeing, they could also address the social and political dimensions encompassing diseases like PD, aiming to alter current understandings and create responses from a clearer view of patient's experiences. 19 If stigma is fundamentally a social-based issue, why put the focus on biomedical variables regarding the patients’ body, when it would be more relevant to explore factors in direct association with social discrimination and stigma like socioeconomic status, prior experience of trauma, accessibility to healthcare specialists or access to caregiving. 20 This way, the authors would be placing the burden of the stigma where it belongs, outside patients' bodies, both in clinical practice and in research. Conflicts of interest The authors declare no conflicts of interest.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Parkinson disease

          Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, Parkinson disease is associated with many non-motor symptoms that add to overall disability. The underlying molecular pathogenesis involves multiple pathways and mechanisms: α-synuclein proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal transport and neuroinflammation. Recent research into diagnostic biomarkers has taken advantage of neuroimaging in which several modalities, including PET, single-photon emission CT (SPECT) and novel MRI techniques, have been shown to aid early and differential diagnosis. Treatment of Parkinson disease is anchored on pharmacological substitution of striatal dopamine, in addition to non-dopaminergic approaches to address both motor and non-motor symptoms and deep brain stimulation for those developing intractable L-DOPA-related motor complications. Experimental therapies have tried to restore striatal dopamine by gene-based and cell-based approaches, and most recently, aggregation and cellular transport of α-synuclein have become therapeutic targets. One of the greatest current challenges is to identify markers for prodromal disease stages, which would allow novel disease-modifying therapies to be started earlier.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The social psychology of stigma.

            This chapter addresses the psychological effects of social stigma. Stigma directly affects the stigmatized via mechanisms of discrimination, expectancy confirmation, and automatic stereotype activation, and indirectly via threats to personal and social identity. We review and organize recent theory and empirical research within an identity threat model of stigma. This model posits that situational cues, collective representations of one's stigma status, and personal beliefs and motives shape appraisals of the significance of stigma-relevant situations for well-being. Identity threat results when stigma-relevant stressors are appraised as potentially harmful to one's social identity and as exceeding one's coping resources. Identity threat creates involuntary stress responses and motivates attempts at threat reduction through coping strategies. Stress responses and coping efforts affect important outcomes such as self-esteem, academic achievement, and health. Identity threat perspectives help to explain the tremendous variability across people, groups, and situations in responses to stigma.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nonmotor features of Parkinson's disease subtypes.

              Parkinson's disease is highly heterogeneous in early clinical features and later outcomes. This makes classifying subgroups of PD relevant to clinical research and practice, particularly if they are prognostically relevant. Subgroups have been defined both on the basis of motor and nonmotor features, and subgroups have been determined either empirically, based on clinical observation, or using data-driven analytic techniques. Previous studies have examined both the overall number and the nature of nonmotor symptoms and signs in tremor-dominant compared with non-tremor-dominant subtypes, and longitudinal studies identify nonmotor symptoms as important markers of prognosis and important defining features of PD subtypes. Autonomic features seem to preferentially affect individuals with non-tremor-dominant PD subtype early in the disease. Later in the disease cognitive disturbance distinguishes this phenotype. Pathological and neuroimaging studies provide substantial evidence for fundamental biological differences between tremor-dominant and postural instability gait disorder/akinetic-rigid subtypes. Biomarker studies point toward non-tremor-dominant PD as representing more advanced and diffuse neurodegeneration than tremor-dominant PD, encompassing dopaminergic and nondopaminergic as well as synuclein and nonsynuclein (Abeta) pathologies. This aligns with clinical studies that find a higher burden of nonmotor symptoms in non-tremor-dominant PD. The mounting evidence for the relevance of nonmotor features in PD subtypes behooves us to begin to investigate the biological underpinnings of subtypes defined by both motor and nonmotor features. This may be challenging, as PD subtypes are unlikely to be distinct nonoverlapping entities but are more likely to represent typical phenotypes within a multidimensional spectrum resulting from variable contributions of a number of simultaneous pathological processes. © 2016 International Parkinson and Movement Disorder Society.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clinics (Sao Paulo)
                Clinics (Sao Paulo)
                Clinics
                Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
                1807-5932
                1980-5322
                13 February 2022
                Jan-Dec 2022
                13 February 2022
                : 77
                : 100008
                Affiliations
                [0001]Neurology Department, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
                Author notes
                [* ]Corresponding author. tomas.rosa@ 123456unifesp.br
                Article
                S1807-5932(22)00004-7 100008
                10.1016/j.clinsp.2022.100008
                8903808
                35172270
                6e9527b6-5506-4a88-9a77-ebcc7047bb0c
                © 2022 HCFMUSP. Published by Elsevier España, S.L.U.

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 2 November 2021
                : 8 December 2021
                Categories
                Comments

                Medicine
                pd, parkinson's disease,adl, activities of daily living
                Medicine
                pd, parkinson's disease, adl, activities of daily living

                Comments

                Comment on this article